Ishtar Company

Ishtar Bio is a biotechnology company focused on developing next-generation cell therapies for the treatment of solid tumors. The company utilizes its proprietary Multi-Antigen Targeted (MAT) T-cell platform to engineer therapies capable of recognizing multiple tumor antigens simultaneously, aiming to overcome common challenges such as antigen escape and immune evasion. By targeting the complex microenvironment of solid cancers, Ishtar Bio seeks to extend the success of cell therapies beyond hematological malignancies. Headquartered in the San Francisco Bay Area, the company is backed by prominent venture capital firms and is currently advancing its pipeline through pre-clinical development.